The Effect of Proton Pump Inhibitors(PPIs) on Endoscopic Treatment of Walled-off Necrosis (WON)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorQilu Hospital of Shandong University

About this trial

In this multicenter, randomized controlled trial, patients with pancreatic walled-off necrosis (WON) based on inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either receive intravenous infusion or oral administration of continuous proton pump inhibitors (PPIs) or to undergo no PPI (nPPI) therapy after endoscopic ultrasound-guided transluminal drainage/debridement. Clinical data and patient-reported outcomes will be systematically collected at baseline and during follow-up periods. The study aims to assess whether PPI use after EUS-TD (Endoscopic Ultrasonography-Guided Transmural Drainage) increases the number of direct endoscopic necrosectomies required to managing WON. Additionally, the study will investigate the impact of PPI use on the incidence of stent occlusion and postoperative complications following EUS-TD, as well as its effect on the average duration of hospitalization and associated costs for patients with WON.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 years or older and not exceeding 80 years of age.

Patients with a confirmed diagnosis of WON.

Patients requiring endoscopic ultrasound-guided transluminal drainage/debridement therapy.

Patients who have signed informed consent forms.

Disqualifiers

Patients diagnosed with chronic pancreatitis who have not experienced an acute pancreatitis attack within the past three months.

Patients with severe coagulation disorders (International Normalized Ratio [INR] > 1.5).

Patients with significant thrombocytopenia (platelet count < 50 × 10^9/L).

Pregnant women.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Proton Pump Inhibitors

    Drug

    On the day of endoscopic ultrasound-guided transluminal drainage/debridement, patients initiated proton pump inhibitor therapy via intravenous infusion or oral administration.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: receive continuous proton pump inhibitor therapy following EUS-TDExperimental treatment 1 intervention
Group B: No PPI therapy following EUS-TDNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Total number of interventions

The total number of endoscopic interventions required to achieve successful WON treatment, including reinterventions, stents removal, and any other interventions performed during the 6-month follow-up period to manage adverse events or disease-specific events.

Time frame
Within 6 months after EUS-TD

Secondary outcomes

1

Technical Success Rate

Successfully placed stents to drain WON.

Time frame
With 24 hours after EUS-TD
2

Clinical success rate

The lesion size has decreased by more than 50% compared to preoperative measurements, with concurrent symptom relief. No further intervention is required prior to stents removal.

Time frame
Within 1 months after EUS-TD
3

Stent occlusion rate

The stent lumen is obstructed by necrotic tissue, debris, or blood clots, leading to impaired drainage and necessitating reintervention, such as stent replacement or direct endoscopic necrosectomy.

Time frame
Within 6 months after EUS-TD
4

Hospitalization and cost

The hospitalization duration, ICU stay duration, and hospitalization costs related to WON treatment

Time frame
Within 6 months after EUS-TD

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Qilu Hospital of Shandong University

Lead sponsor

960th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Collaborator

Shandong Provincial Hospital

Collaborator

Shengli Oilfield Hospital

Collaborator

Shenzhen People's Hospital

Collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator

Nanfang Hospital, Southern Medical University

Collaborator